Smart Healthcare

Itinai.com light and shadow chase in a bright biomedical labo ad12232e 48e7 4335 b615 18ed42101be9 2
Itinai.com light and shadow chase in a bright biomedical labo ad12232e 48e7 4335 b615 18ed42101be9 2

Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial

“`html

Study Summary: Comparing Chemotherapy Cycles for Small-Cell Lung Cancer

Researchers compared the outcomes of patients with limited-stage small-cell lung cancer (LS-SCLC) who received either 6 cycles or 4-5 cycles of chemotherapy combined with thoracic radiotherapy (TRT).

Key Findings:

  • Patients who received 6 cycles of chemotherapy showed significant improvement in overall survival (OS) and progression-free survival (PFS) compared to those who received 4-5 cycles.
  • The two-year and five-year OS rates were higher in the 6 cycles group than in the 4-5 cycles group.

Practical Implications:

  • Administering 6 cycles of chemotherapy combined with TRT may lead to notably enhanced survival for LS-SCLC patients.
  • Physicians should consider the potential benefits of 6 cycles of chemotherapy when treating LS-SCLC patients.

“`

Dr M. Trenton

AI-Powered Health Tools

Interactive AI Tools to Help You Understand Your Health

Solutions for Smart Healthcare

Clinical Research